Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exercise Substrate Utilisation and Endurance Performance Following Short-term Manipulation of Dietary Fat Intake

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02568592
Recruitment Status : Unknown
Verified May 2016 by University of Birmingham.
Recruitment status was:  Active, not recruiting
First Posted : October 6, 2015
Last Update Posted : May 13, 2016
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
University of Birmingham

Brief Summary:

The capacity to burn fat as fuel for exercise may have important implications for sporting performance, with dietary fat intake positively influencing this ability.

Endurance performance and the ability to burn fat will be measured in women runners following the consumption of 3 diets varying in the amount of fat and carbohydrate.


Condition or disease Intervention/treatment Phase
Dietary Modification Dietary Supplement: High Fat Dietary Supplement: Normal Dietary Supplement: Normal + Extra Fat Not Applicable

Detailed Description:
Dietary fat intake positively influences the ability to burn fat during exercise in women but not men, whereas carbohydrate intake negatively influences fat oxidation in both sexes. The independent nature of dietary fat intake as a predictor of the ability to burn fat in women suggests that in conditions of adequate carbohydrate intake providing additional fat may increase fat oxidation in women whereas it does not in men. It is of interest to explore if indeed women are responsive (i.e., increase in fat oxidation) to short-term increases in dietary fat intake induced by overfeeding (adequate carbohydrate) or if as appears to be the case in men reduced carbohydrate intake as typically employed in high-fat, low carbohydrate dietary studies is also a prerequisite for enhancing fat oxidation in women, and whether this translates into a difference in exercise endurance performance.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Exercise Substrate Utilisation and Endurance Performance Following Short-term Manipulation of Dietary Fat Intake in Women
Study Start Date : March 2015
Estimated Primary Completion Date : June 2016
Estimated Study Completion Date : June 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: High Fat
High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)
Dietary Supplement: High Fat
High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)

Experimental: Normal
Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)
Dietary Supplement: Normal
Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)

Experimental: Normal + Extra Fat
Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORM (Normal), with an additional 30% extra energy coming from fat.
Dietary Supplement: Normal + Extra Fat
Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORMAL, with an additional 30% extra energy coming from fat.




Primary Outcome Measures :
  1. Rates of fat oxidation during exercise [ Time Frame: 90 minutes of sub-maximal exercise ]
    Rates of fat oxidation to be measured via indirect calorimetry during 90 minutes of submaximal exercise


Secondary Outcome Measures :
  1. 5km running performance [ Time Frame: Immediately following measurement of Primary Outcome measure ]
    Time to complete 5km on a treadmill

  2. Change in plasma glucose concentration [ Time Frame: 90 minutes sub-maximal exercise ]
    Area under the plasma concentration versus time curve (AUC) of glucose

  3. Change in Free Fatty Acid concentration [ Time Frame: 90 minutes sub-maximal exercise ]
    Area under the plasma concentration versus time curve (AUC) of Free Fatty Acid

  4. Change in plasma glycerol concentration [ Time Frame: 90 minutes sub-maximal exercise ]
    Area under the plasma concentration versus time curve (AUC) of glycerol



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • BMI >17.0 < 25 kg/m2
  • Good General Health
  • Accustomed to vigorous physical activity
  • Run > 2 times per week
  • V̇O2max >50ml/kg/min
  • Weight Stable > last 6months
  • Non Smoker
  • Pre-menopausal, and either eumenorrheic and regularly menstruating, or using monophasic hormonal oral contraceptives for > 3 months.

Exclusion Criteria:

  • Currently taking part in another scientific/clinical study
  • Taking any prescription drug / supplement thought to influence metabolism
  • Following unusual dietary practices (such as intermittent fasting or low carbohydrate diets)
  • Pregnant
  • Breast Feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02568592


Locations
Layout table for location information
United Kingdom
University of Birmingham
Birmingham, West Midlands, United Kingdom, B15 2TT
Sponsors and Collaborators
University of Birmingham
GlaxoSmithKline
Investigators
Layout table for investigator information
Principal Investigator: Gareth A Wallis, PhD University of Birmingham
Layout table for additonal information
Responsible Party: University of Birmingham
ClinicalTrials.gov Identifier: NCT02568592    
Other Study ID Numbers: ERN_15-0012
First Posted: October 6, 2015    Key Record Dates
Last Update Posted: May 13, 2016
Last Verified: May 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No